Athira Pharma Files 8-K Report

Ticker: LONA · Form: 8-K · Filed: Oct 3, 2025 · CIK: 1620463

Athira Pharma, INC. 8-K Filing Summary
FieldDetail
CompanyAthira Pharma, INC. (LONA)
Form Type8-K
Filed DateOct 3, 2025
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001, $1.00
Sentimentneutral

Sentiment: neutral

Topics: 8-K, other-events

Related Tickers: ATHA

TL;DR

Athira Pharma (ATHA) filed an 8-K for 'Other Events' on Oct 2nd. Details TBD.

AI Summary

On October 2, 2025, Athira Pharma, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding the nature of these events, any financial implications, or involved parties were provided in the excerpt.

Why It Matters

This filing signals a material event has occurred at Athira Pharma, requiring disclosure to investors. The lack of detail in the provided excerpt necessitates further investigation to understand the event's significance.

Risk Assessment

Risk Level: medium — The filing of an 8-K for 'Other Events' suggests a potentially significant development, but the lack of specific information creates uncertainty and thus a medium risk level.

Key Players & Entities

FAQ

What specific event(s) are being reported under 'Other Events'?

The provided excerpt does not specify the nature of the 'Other Events' reported by Athira Pharma, Inc. on October 2, 2025.

When was the report filed?

The report was filed as of October 3, 2025.

What is Athira Pharma's principal executive office address?

Athira Pharma's principal executive offices are located at 18706 North Creek Parkway, Suite 104, Bothell, WA 98011.

What was Athira Pharma's former company name?

Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc.

What is the SEC file number for Athira Pharma?

Athira Pharma's SEC file number is 001-39503.

Filing Stats: 497 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2025-10-03 09:11:18

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Athira Pharma, Inc. Date: October 3, 2025 By: /s/ Mark Litton Mark Litton President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing